An Overview of Infliximab, Etanercept, Efalizumab, and Alefacept as Biologic Therapy for Psoriasis

Clinical Therapeutics

Volumn 25, Issue 10, 2003, Pages 2487-2505

  Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Biologic therapy; Cytokine; Psoriasis; T cell

Indexed keywords

ALEFACEPT; CYCLOSPORIN; DAPSONE; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; STEROID;

ABDOMINAL DISCOMFORT; ALLERGIC REACTION; APLASTIC ANEMIA; CHILL; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION; INJECTION PAIN; LIVER TOXICITY; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN DISEASE; THORAX PAIN; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0242425724     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80313-2     Document Type: Article

References (41)

1. Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM. Biologic therapy for psoriasis: A brief history, II. Cutis. 2001;68:367-372.
2. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol. 2002;138:657-663.
3. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet. 2001;357:1842-1847.
4. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46: 886-891.
5. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001;144:587-589.
6. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41:449-452.
7. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol. 2002;138: 644-648.
8. Gottlieb AB, Li S, Evans R, Menter A. Infliximab in the treatment of psoriasis: Results from the first 10 weeks of a phase II trial. Poster presented at: American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, Calif.
9. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol. 2003;44:116-120.
10. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138: 686-688.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001:345;1098-1104.
12. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003;29:185-202.
13. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
14. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
15. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003;22:56-61.
16. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol. 2000;12:49-52.
17. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939.
18. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
19. Remicade [package insert]. Malvern, Pa: Centocor Corporation; 2002.
20. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-580.
21. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet. 2000;356:385-390.
22. Gottlieb AB, Matheson R, Lowe NJ, Zitnik RJ. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol. 2002;119:234. Abstract.
23. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy. Br J Dermatol. 2002;146:118-121.
24. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213-216.
25. Leonardi C, Gottlieb AB, Zitnik R. Efficacy and safety of ENBREL (etanercept) in patients with psoriasis. Poster presented at: International Investigative Dermatology 2003; April 30-May 4, 2003; Miami Beach, Fla. Poster 0409.
26. Weinberg JM, Saini R. Biologic therapy for psoriasis: The tumor necrosis factor inhibitors infliximab and etanercept. Cutis. 2003;71:25-29.
27. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-811.
28. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000;42:428-435.
29. Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol. 2001;45:665-674.
30. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591-600.
31. Gordon KB, Leonardi C, Tyring S, et al. Efalizumab (anti-CD11a) is safe and effective in the treatment of psoriasis: Pooled results of the 12-week first treatment period from 2 phase III trials. J Invest Dermatol. 2002;119:242. Abstract.
32. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.
33. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
34. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
35. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol. 2003;148:784-788.
36. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003;49:160-161.
37. Wang LC, Medenica MM, Shea CR, Busbey S. Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis. J Am Acad Dermatol. 2003;49:157-158.
38. McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol. 2003;36:411-413.
39. Lobel EZ, Korelitz BI, Warman JI. Red man syndrome and infliximab. J Clin Gastroenterol. 2003;36:186. Letter.
40. Edwards KR, Mowad CM, Tyler WB. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol. 2003;2:184-187.
41. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401-403.